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Background: The dibenzylbutyrolactone lignan (−)-hinokinin (HK) was derived by partial synthesis from
(−)-cubebin, isolated from the dry seeds of the pepper, Piper cubeba. Considering the good trypanosomicidal
activity of HK and recalling that natural products are promising starting points for the discovery of novel potentially
therapeutic agents, the aim of the present study was to investigate the (anti) mutagenic ∕ genotoxic activities of HK.
Methods: The mutagenic ∕ genotoxic activities were evaluated by the Ames test on Salmonella typhimurium strains
TA98, TA97a, TA100 and TA102, and the comet assay, so as to assess the safe use of HK in the treatment of Chagas’
disease. The antimutagenic ∕antigenotoxic potential of HK were also tested against the mutagenicity of a variety of
direct and indirect acting mutagens, such as 4- nitro-o-phenylenediamine (NOPD), sodium azide (SA), mitomycin C
(MMC), benzo[a]pyrene (B[a]P), aflatoxin B1 (AFB1), 2-aminoanthracene (2-AA) and 2-aminofluorene (2-AF), by the
Ames test, and doxorubicin (DXR) by the comet assay.
Results: The mutagenicity ∕genotoxicity tests showed that HK did not induce any increase in the number of
revertants or extent of DNA damage, demonstrating the absence of mutagenic and genotoxic activities. On the
other hand, the results on the antimutagenic potential of HK showed a strong inhibitory effect against some direct
and indirect-acting mutagens.
Conclusions: Regarding the use of HK as an antichagasic drug, the absence of mutagenic effects in animal cell and
bacterial systems is encouraging. In addition, HK may be a new potential antigenotoxic ∕ antimutagenic agent from
natural sources. However, the protective activity of HK is not general and varies with the type of DNA
damage-inducing agent used.
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(−)-Hinokinin (HK – Figure 1), a dibenzylbutyrolactone
lignan, was derived by partial synthesis from (−)-cubebin
(Figure 1) isolated from the dry seeds of Piper cubeba
[1] and proved to be a potential candidate for the devel-
opment of a new drug to treat Chagas’ disease [2,3]. The* Correspondence: flaviabiomed@yahoo.com.br
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reproduction in any medium, provided the ordrugs currently used to treat Chagas’ disease are two nitro-
heterocyclic drugs, the nitrofuran nifurtimox (LampitW),
whose production has now been discontinued, and the
2-nitroimidazole benznidazole (RochaganW) [4]. These
drugs have demonstrated several limitations in use, in part
due to their low bioavailability, their limited efficacy against
the various stages of the disease and the development of
parasite resistance. The other main contraindication of
both drugs is their significant toxicity [5].
The most frequent side effects of these drugs include
anorexia, vomiting, peripheral polyneuropathy and allergicl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Chemical structures of (−)-cubebin and (−)-hinokinin.
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been clearly proved in the case of nifurtimox [6]. Also,
benznidazole has exhibited genotoxic effects in vitro [7]
and significant in vivo alterations [8]. For this reason, the
development of safer and more effective drugs for Chagas’
disease is an urgent priority [5].
Studies have shown that HK has higher trypanosomicidal
activity than benznidazole against epimastigote forms and
a similar activity against amastigote forms [2,9], which
aroused considerable scientific interest in this lignan.
Moreover, HK exhibits activity against oral pathogens,
including Streptococcus mutans [10], antioxidant activity
in vitro [1], analgesic and anti-inflammatory activities [11],
as well as antimutagenic activity by the micronucleus test,
in vivo [1] and in vitro [12].
In light of the good trypanosomicidal activity of HK
and given that natural products are promising sources of
novel potentially therapeutic agents, the aim of the
present study was to investigate its mutagenic and geno-
toxic activities by the Ames and comet assays, respect-
ively, to assess the safety of using HK in the treatment of
Chagas’ disease. In the absence of such activity, the anti-
mutagenic and antigenotoxic potential would also be
tested, with a view to discovering antiparasite agents that
can protect the genetic material against damage.
Methods
Isolation of (−)-cubebin
Powdered seeds from commercially available Piper cubeba
L. fruits were exhaustively extracted by maceration with96% ethanol. The crude extract was concentrated by evap-
oration and partitioned between hexane and methanol/
water (9:1) phases, providing 430 g of the dried methanol/
water fraction. This mass was submitted to repeated
column chromatography on 1.0 kg silica gel (12 × 120 cm).
The cubebin-rich fractions (hexane/dichloromethane 1:1
and 100% dichloromethane) were subjected to repeated
crystallization in hexane/acetone to provide crystalline
(−)-cubebin (37 g), mp 130–131°C, [α]D
26–8.12° (c 0.46,
CHCl3). The chemical structure was confirmed by
1H
NMR and IR, by comparison with published data [13].
Purity was estimated to be 99% by both HPLC and spectral
data analysis.
Preparation of (−)-hinokinin
(−)-Cubebin (0.5004 g in 10 mL dichloromethane) was
treated with two equivalents (2.32 mM) of pyridinium
chlorochromate at room temperature and the reaction
mixture was stirred for 12 h. The solvent was removed
under vacuum and the residue was submitted to chroma-
tography on silica gel, eluted with hexane-ethyl acetate
(4:1), yielding 0.4926 g (98%) of an oily product ([α]D
26–30
(26°C) (c 0.99, CHCl3)):
1H-NMR δ (CDCl3) 6.8-6.4 (m, 1
H), 5.9 (sl, 2 H), 4.15 (dd, 1 H, J = 7.1 Hz and J = 9.3 Hz),
3.85 (dd, 1 H, J = 7.1 Hz and J = 9.1 Hz), 3.0 (dd, 1 H, J =
5.1 Hz and J = 14.2 Hz), 2.85 (dd, 1 H, J = 7.3 Hz and J =
14.2 Hz), 2.6 (d, 1 H, J = 7.1 Hz), 2.55 (m, 1 H), 2.45(d, 1 H,
J = 8,6 Hz), 2.4 (m, 1 H); 13C-NMR δ (CDCl3) 178.4, 147.9,
147.8, 146.5, 146.4, 131.6, 131.3, 122.2, 121.55, 109.4, 108.8,
108.4, 108.3, 101.0, 71.2, 46.4, 41.3, 38.4, 34.8 [9].
Chemicals and culture media
Dimethylsulfoxide (DMSO), nicotinamide adenine dinucleo-
tide phosphate sodium salt (NADP), D-glucose-6-phosphate
disodium salt, magnesium chloride, L-histidine mono-
hydrate, D-biotin, 4-nitro-o-phenylenediamine (NOPD),
sodium azide (SA), mitomycin C (MMC), benzo[a]pyrene
(B[a]P), aflatoxin B1 (AFB1), 2-amino-anthracene (2-AA)
and 2-amino-fluorene (2-AF) were purchased from Sigma
Chemical Co. (St. Louis, MO, USA). Doxorubicin (DXR)
was purchased from Pharmacia Brasil Ltda, Brazil, and
dissolved in distilled water immediately before treatment.
Oxoid Nutrient Broth No. 2 (Oxoid, England) and Difco
Bacto Agar (Difco, USA) were used as bacterial media.
D-glucose, magnesium sulfate, citric acid monohydrate,
anhydrous dibasic potassium phosphate, sodium ammo-
nium phosphate, monobasic sodium phosphate, dibasic
sodium phosphate and sodium chloride were purchased
from Merck (Whitehouse Station, NJ, USA).
Cell line and culture conditions
Chinese hamster lung fibroblasts (V79) were kindly
supplied by Professor Cólus (Universidade Estadual de
Londrina (UEL), Paraná, Brazil). Cells were maintained
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HAM-F10 (Sigma-Aldrich) plus DMEM (Sigma-Aldrich,
1:1) culture medium supplemented with 10% fetal bovine
serum (Nutricell), antibiotics (0.01 mg mL−1 streptomycin
and 0.005 mg mL−1 penicillin; Sigma-Aldrich) and 2.38
mg mL−1 Hepes (Sigma-Aldrich), at 37°C in a BOD-type
chamber. Under these conditions, the average cell cycle
time was 12 h.
Comet assay
The protocol for the determination of the genotoxicity
and antigenotoxicity of HK at various concentrations
(0.5 - 128 μM) was performed in triplicate on three
different days, to ensure reproducibility. HK was first
dissolved in a mixture of methanol (100 μL) and distilled
water (900 μL). The final concentration of methanol in
the culture was 0.1%. The choice of concentrations was
based on the results of previous experiments with HK
[12]. In the experiments, 3 × 105 cells (V79) were seeded
into tissue-culture flasks, incubated for two cycles (24 h)
in complete HAM-F10/DMEM medium, washed with
phosphate buffer saline (PBS), and then subjected to one
of the following treatments, in serum-free medium, for 3
h. To assess genotoxicity, the cells were treated with
each concentration of HK alone, while for antigenotoxi-
city, they were treated with the mutagen DXR (0.3 μM)
in combination with each HK concentration. Positive
(DXR) and negative controls were also included in the
test. At the end of the treatment, the cells were washed
with ice-cold PBS and trypsinized with 200 μL trypsin.
After 3 min, the cells were gently resuspended in
complete medium and 20 μL of the cell suspension was
immediately used for the test.
The procedures described by Singh et al. [14] were
adopted, with minor modifications, as described in detail
by Speit and Hartmann [15] and reviewed by Burlinson
et al. [16]. Briefly, a microscope slide was covered with a
base layer of 1.5% normal-melting agarose (Invitrogen)
and 20 μL of the test cells suspended in 120 μL 0.5%
low-melting agarose (Invitrogen) at 37°C was then
spread over the base layer. A coverslip was added and
the agarose allowed to solidify at 4°C for 15 min. Next,
the coverslip was gently removed and the slides were
immersed in freshly prepared lysing solution consisting
of 89 mL stock solution (2.5 M NaCl, 100 mM EDTA,
10 mM Tris, pH 10.0, and 1% sodium lauryl sarcosine),
10 mL DMSO and 1 mL Triton X-100, pH 10.0, at 4°C,
for at least 20 h, protected from light. At the end of this
period, the slides were transferred to an electrophoresis
chamber containing a high pH (>13.0) buffer (300 mM
NaOH, 1 mM EDTA) and incubated at 4°C for 20 min to
allow the DNA to unwind. A current of 25 V (1.0 V cm−1,
300 mA) was applied for 20 min. The slides were then
submerged in a neutralization buffer (0.4 M Tris - HCl,pH 7.5) for 15 min, dried at room temperature and fixed
in 100% ethanol for 10 min.
The slides were stained with 100 μL ethidium bromide
(20 μg ml−1) and covered with a coverslip. All the slides
in the experiment were coded before analysis. The
stained nucleoids were immediately evaluated at 1000x
magnification under a Nikon fluorescence microscope
fitted with a 515–560 nm excitation filter and a 590 nm
barrier filter.
For each treatment, the extent and distribution of DNA
damage indicated by the comet assay were evaluated by
examining 100 randomly selected and non-overlapping
cells on the slides (i.e. 300 nucleoids per treatment). For
each slide, the cells were visually scored and allocated to
one of four classes (0, 1, 2 and 3), according to tail size, as
follows: class 0, undamaged, no tail; class 1, a short tail
whose length was smaller than the diameter of the comet
head (nucleus); class 2, tail length between 1 and 2 times
the diameter of the head; and class 3, maximally damaged:
a long tail measuring more than twice the diameter of the
head. The few comets containing no head and those with
almost all DNA in the tail, or with a very wide tail, were
excluded from the analysis since they may arise from dead
cells [17].
The total score for 300 comets was calculated by the
formula shown below:
Score ¼ 1 n1ð Þ þ 2 n2ð Þ þ 3 n3ð Þ
where n = number of cells in each class analyzed. Thus,
the total score ranged from 0 to 300. The percentage
reduction of genotoxic agent-induced damage by HK
was calculated as in Waters et al. [18], with the following
formula:
%Reduction ¼ A B=A Cð Þ  100
where A is the mean score in the treatment with DXR
(positive control), B the mean score in the antigenotoxic
treatment (HK plus DXR) and C the mean score in the
negative control.
Cell viability was evaluated for each treatment by Trypan
blue staining. Briefly, a solution of 50 μL Trypan blue
(0.4%) freshly prepared in distilled water was mixed with
50 μL of each cell suspension, spread onto a microscope
slide and covered with a coverslip. Non-viable cells
appeared blue. At least 200 cells were counted per culture.
The results were evaluated by analysis of variance
(ANOVA) and the Tukey test at P < 0.05, the experimental
criterion being the significance of the response to HK
treatment in relation to the negative control, in the geno-
toxicity assay, and in relation to the positive control when
the antigenotoxicity of HK was determined as its capacity
to reduce the DNA damage induced by DXR.
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Mutagenic activity was evaluated by the Salmonella/
microsome assay, using the Salmonella typhimurium
tester strains TA98, TA100, TA97a and TA102, kindly pro-
vided by Dr. B.N. Ames (Berkeley, CA, USA), with (+ S9)
and without (− S9) metabolization, by the pre-incubation
method [19]. The strains were grown from frozen cultures
overnight for 12–14 h in Oxoid Nutrient Broth No. 2.
The metabolic activation mixture (S9 fraction), prepared
from livers of Sprague–Dawley rats treated with the poly-
chlorinated biphenyl mixture Aroclor 1254 (500 mg/ kg),
was purchased from Molecular Toxicology Inc. (Boone,
NC, USA) and freshly prepared before each test. The
metabolic activation system consisted of 4% S9 fraction,
1% 0.4 M MgCl2, 1% 1.65 M KCl, 0.5% 1 M D-glucose-
6-phosphate disodium and 4% 0.1 M NADP, 50% 0.2 M
phosphate buffer and 39.5% sterile distilled water [19].
For the determination of the mutagenic activity, five
different concentrations of HK (9.75 – 78.0 μg∕ plate),
diluted in DMSO, were assayed. The concentrations of
HK were selected on the basis of a preliminary toxicity
test. In all subsequent assays, the upper limit of the dose
range tested was either the highest non-toxic dose or the
lowest toxic dose determined in this preliminary assay.
Toxicity was detected either as a reduction in the number
of histidine revertants (His+), or as a thinning of the auxo-
trophic background (i.e., background lawn). The various
concentrations of HK to be tested were added to 0.5 mL of
0.2 M phosphate buffer, or to 0.5 mL of 4% S9 mixture,
with 0.1 mL of bacterial culture and then incubated at 37°C
for 20–30 min. Next, 2 mL of top agar was added and the
mixture poured on to a plate containing minimal agar.
The plates were incubated at 37°C for 48 h and the
His+ revertant colonies were counted manually. All
experiments were analyzed in triplicate. The results were
analyzed with the statistical software package Salanal 1.0
(U.S. Environmental Protection Agency, Monitoring
Systems Laboratory, Las Vegas, NV,from Research Triangle
Institute, RTP,NC, USA), adopting the Bernstein et al. [20]
model. The data (revertants/ plate) were assessed by ana-
lysis of variance (ANOVA), followed by linear regression.
The mutagenic index (MI) was also calculated for each
concentration tested, this being the average number of
revertants per plate with the test compound divided by the
average number of revertants per plate with the negative
(solvent) control. A test solution was considered mutagenic
when a dose–response relationship was detected and a
two-fold increase in the number of mutants (MI ≥ 2) was
observed for at least one concentration [21]. The standard
mutagens used as positive controls in experiments without
S9 mix were NOPD (10 μg/ plate) for TA98 and TA97a,
SA (1.25 μg/ plate) for TA100 and MMC (0.5 μg/ plate) for
TA102. In experiments with S9 activation, 2-AA (1.25 μg
/plate) was used with TA98, TA97a and TA100 and 2-AF(10 μg/ plate) with TA102. DMSO (50 μL/ plate) served as
the negative (solvent) control.
The antimutagenicity assay was conducted by means
of the same procedure as the mutagenicity assay, except
that HK was associated with known mutagens in tests
with and without metabolic activation. In these tests, the
direct-acting mutagens were 10.0 μg/ plate of NOPD
(for S. typhimurium TA98 and TA97a), 1.25 μg/ plate of
SA (for S. typhimurium TA100) and 0.5 μg/ plate of
MMC (for S. typhimurium TA102), in the assay without
metabolic activation, and the indirect-acting mutagens
were 1.0 μg/ plate of B[a]P (for S. typhimurium TA98),
0.5 μg/ plate of AFB1 (for S. typhimurium TA100), 1.25
μg/ plate of 2-AA (for S. typhimurium TA97a) and 10
μg/ plate of 2-AF (for S. typhimurium TA102), in the
assay with metabolic activation. All the plates were incu-
bated at 37°C for 48 hours, and the number of revertant
colonies per plate was counted manually. The entire
assay was performed in triplicate.
The antimutagenicity results were expressed as percent
inhibition (the ability of the compounds to inhibit the ac-
tion of the known mutagen). This was calculated as follows:
Inhibition %ð Þ ¼ 100 T=Mð Þ  100½ 
where T is the number of revertant colonies in the plate
containing mutagen and compounds and M is the number
of revertant colonies in the plate containing only the
mutagen [22].
No antimutagenic effect was recorded when the
inhibition was lower than 25%, a moderate effect for a
value between 25% and 40%, and strong antimutagenicity
for values greater than 40% [23,24].
Cell viability was also determined for each antimuta-
genesis experiment, to assess the potential bactericidal
effect of the mutagens. A substance was considered
bactericidal when the bacterial survival was less than
60% of that observed in the negative control [24,25].
Results
Comet assay
The results for V79 cells treated with HK by comet assay
are shown in Table 1. No significant difference was
observed between cultures treated with HK and the
negative control group (P>0.05), demonstrating the
absence of genotoxicity. On the other hand, a significant
increase in the rate of DNA damage was observed in
cultures treated with DXR, relative to the negative control,
as expected.
In the treatments with HK associated with DXR, the
lower concentrations of HK (0.5; 1.0 and 2.0 μM) signifi-
cantly reduced the extent of DNA damage induced by
DXR. This significant reduction in the frequency of DNA
damage ranged from 60.8 to 76.0%. The gradual increase




Class* Score* Reduction %
0 1 2 3
Control 84.3 ± 9.0 10.0 ± 4.0 2.3 ± 2.0 1.6 ± 2.0 20.3 ± 13.0 -
MeOH 87.0 ± 7.0 11.0 ± 5.5 2.3± 1.5 0 18.0 ± 5.1 -
0.5 81.6 ± 4.9 12.3± 3.5 4.3 ± 3.7 5.0 ± 2.8 26.0 ± 13.2 -
1.0 87.0 ± 5.1 11.0 ± 5.2 1.3 ± 0.5 0 13.0 ± 5.0 -
2.0 83.0 ± 3.7 14.0 ± 2.5 2.0 ± 2.0 0 18.0 ± 5.0 -
32 89.0 ± 2.0 10.0 ± 2.0 0.3 ± 0.5 0.6 ± 1.1 9.6 ± 2.3 -
64 88.0 ± 3.6 11.0 ± 4.0 0.6 ± 1.0 1.0 ± 1.0 13.0 ± 3.4 -
128 89.0 ± 1.5 10.0 ± 1.5 1.0 ± 0.0 0 12.0 ± 1.5 -
DXR 41.0 ± 12.0 36.0 ± 12.7 18.0 ± 2.0 4.0 ± 2.5 86.0 ± 11.5a -
DXR + MeOH 46.3 ± 6.8 30.0 ± 6.0 16.3 ± 5.6 6.6 ± 3.0 83.3 ± 14.5a -
0.5 + DXR 73.0 ± 7.0 20.0 ± 7.5 4.6 ± 1.5 2.0 ± 2.0 36.0 ± 6.1a,b 76.0
1.0 + DXR 68.0 ± 2.0 20.6 ± 2.5 8.0 ± 2.0 3.3 ± 0.5 46.0 ± 3.0a,b 60.8
2.0 + DXR 65.0 ± 6.8 27.0 ± 6.6 4.3 ± 2.3 2.6 ± 1.6 44.3 ± 9.2a,b 63.4
32 + DXR 35.0 ± 5.0 33.0 ± 3.0 30.0 ± 4.1b 1.0 ± 1.0 97.0 ± 10.0a -
64 + DXR 32.0 ± 6.1 39.0 ± 3.7 26.0 ± 2.0 2.0 ± 2.0 97.0 ± 10.0a -
128 + DXR 28.0 ± 6.6 40.0 ± 1.0 29.0 ± 5.2b 3.0 ± 2.5 106.0 ± 16.0a -
HK = (−)-hinokinin; MeOH= methanol (0.1%); DXR= doxorubicin (0.3 μM).
The different doses (0.5, 1.0, 2.0, 32, 64 and 128 μM) correspond to HK.
*Values are the means ± standard deviation.
a Significantly different from control (P<0.05).
b Significantly different from the DXR group (P<0.05).
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increase in the reduction of DXR-induced genotoxicity,
thus demonstrating the absence of a dose–response
relationship (Table 1).
However, at the higher concentrations of HK (32; 64
and 128 μM) associated with DXR, the extent of DNA
damage did not differ significantly from the frequencies
observed in the DXR treatment. The data also showed
that the extent of class 2 damage was higher in treat-
ments with HK and DXR than in the group treated with
DXR, which was statistically significant at concentrations
of 32 and 128 μM (Table 1).
Comet class 0 was the most frequent among cultures
treated with various doses of HK, negative and solvent
controls, and lower concentrations of HK plus DXR,
whereas comet classes 1 and 2 were the most frequent
among cultures treated with only with DXR or MeOH
plus DXR (Table 1). Cell viability was higher than 95% in
all treatments.
There was no significant difference in the extent of
DNA damage between cultures treated with the solvent
plus DXR and the positive control.
Ames test
Table 2 shows the mean number of revertants/plate (M),
the standard deviation (SD) and the mutagenic index(MI) after the treatments with HK, observed in S.
typhimurium strains TA98, TA100, TA102 and TA97a,
in the presence (+S9) and absence (−S9) of metabolic
activation. The mutagenicity assays show that HK did
not induce any increase in the number of revertant
colonies relative to the negative control, indicating the
absence of any mutagenic activity.
On the other hand, the results obtained in the tests
for antimutagenic potential of HK, presented in
Table 3, show a strong inhibitory effect against direct
and indirect-acting mutagens, for strains TA98,
TA100, TA102 and TA97a. The results are expressed
as mean number of revertants/ plate (M), the standard
deviation (SD) and the percent inhibition of mutagenic
activity of a sample containing a mixture of mutagen
and HK, relative to the mutagenicity of the mutagen
alone.
When strain TA98 was used in association with
NOPD, a moderate antimutagenic effect was observed
for HK (26% inhibition). In experiments with metabolic
activation, for strain TA98, the mutagenicity of B[a]P was
significantly reduced by 59%.
HK did not reduce mutagenesis induced by SA, MMC
or NOPD, in the absence of metabolic activation, when
strains TA100, TA102 and TA97a were used, respect-
ively. However, HK did inhibit mutation induced by the
Table 2 Revertants/ plate, standard deviation and mutagenicity index (in brackets) for the strains TA98, TA100, TA102
and TA97a of S. typhimurium after treatment with various doses of HK, with (+S9) and without (−S9) metabolic
activation
Treatments Number of revertants (M ± SD)/ plate and MI
μg/plate TA 98 TA 100 TA 102 TA 97a
- S9 + S9 - S9 + S9 - S9 + S9 - S9 + S9
HK 0.0a 22 ± 2 32 ± 1 132 ± 6 123 ± 1 243 ± 4 391 ± 8 164 ± 4 163 ± 2
9.7 18 ± 4 (0.8) 32 ± 1 (1.0) 134 ± 4 (1.0) 130 ± 6 (1.1) 238 ± 8 (1.0) 376 ± 7 (1.0) 165 ± 5 (1.0) 172 ± 10 (1.0)
19.5 23 ± 3 (1.0) 34 ± 3 (1.1) 129 ± 6 (1.0) 128 ± 6 (1.0) 231 ± 8 (0.9) 363 ± 3 (0.9) 165 ± 9 (0.9) 187 ± 3 (1.1)
39.0 25 ± 3 (1.1) 33 ± 4 (1.0) 134 ± 5 (1.0) 115 ± 8 (0.9) 213 ± 4 (0.9) 354 ± 4 (0.9) 146 ± 5 (0.9) 166 ± 5 (1.0)
58.5 25 ± 2 (1.1) 28 ± 1 (0.8) 112 ± 3 (0.8) 134 ± 2 (1.1) 201 ± 6 (0.8) 398 ± 9 (1.0) 175 ± 4 (1.1) 172 ± 2 (1.0)
78.0 24 ± 5 (1.1) 31 ± 2 (1.0) 140 ± 9 (1.1) 120 ± 8 (1.0) 186 ± 2 (0.8) 402 ± 3 (1.0) 163 ± 8 (1.0) 146 ± 4 (0.9)
Ctrol + 1347 ± 88b 1567 ± 115e 1582 ± 98c 1456 ± 78e 1656 ± 60d 1932 ± 97f 1766 ± 49b 1789 ± 89e
HK = (−)-Hinokinin; M ± SD = mean and standard deviation; MI = mutagenicity index; aNegative control: dimethylsulfoxide (DMSO - 50 μL/ plate); Ctrol + = Positive
control - b4 -nitro-o-phenylenediamine (NOPD – 10.0 μg/ plate – TA98, TA97a); csodium azide (1.25 μg/ plate – TA100); dmitomycin (0.5 μg/ plate – TA102), in the
absence of S9 and e2-anthramine (1.25 μg/ plate – TA 97a, TA98, TA100); f2-aminofluorene (10.0 μg/ plate – TA102), in the presence of S9.
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decreases in the mutagenicity of 2-AF in TA102 (52%)
and a strong antimutagenic effect against mutations
induced by 2-AA in TA97a (67% inhibition). The highest
observed percent inhibition of mutagenicity (89%)Table 3 Antimutagenic activity expressed as the mean and st
inhibition by HK of direct (−S9) and indirect (+S9) mutagens,
typhimurium
Treatments Number of revertants
HK TA 98
μg/plate − S9 % inhibition + S9 % inhibit
Ctrol + NOPD B[a]P
638 + 30 1244 + 38
9.7 525 + 7 18* 874 + 21 31**
19.5 507 + 15 21* 869 + 4 32**
39.0 477 + 5 26** 813 + 18 36**
58.5 521 + 9 19* 618 + 6 52***
78.0 480 + 16 25** 539 + 32 59***
TA 102
μg/plate - S9 % inhibition + S9 % inhibit
Ctrol + MMC 2-AF
1184 + 42 1279 + 12
9.7 1236 + 17 - 852 + 21 42***
19.5 1201 + 23 - 855 + 22 42***
39.0 1317 + 14 - 820 + 19 46***
58.5 1017 + 56 18* 754 + 9 52***
78.0 979 + 51 22* 757 + 29 52***
HK = (−)-Hinokinin; M ± SD = mean and standard deviation; Ctrol + = positive Cont
SA = sodium azide (1.25 μg/ plate – TA100); MMC = mitomycin (0.5 μg/ plate – TA1
AFB1 = aflatoxin B1 (0.5 μg/ plate – TA 100); 2-AA = 2-anthramine (1.25 μg/ plate – TA
* no antimutagenic effect (< 25% inhibition).
** moderate effect (25% - 40% inhibition).
*** strong antimutagenic effect (> 40% inhibition).achieved with HK was in strain TA100, in the presence
of AFB1. Furthermore, HK potentiated NOPD -induced
clastogenicity in the strain 97a: the number of revertents
observed for the combined treatment was higher than
that observed for the positive control alone.andard deviation of number of revertants and percent
tested on strains TA98, TA100, TA102 and TA 97a of S.
(M ± SD)/ plate and % of inhibition
TA 100
ion − S9 % inhibition + S9 % inhibition
SA AFB1
1219 + 46 1607 + 79
1139 + 20 7* 1183 + 30 30**
1112 + 34 9* 976 + 18 45***
1169 + 32 5* 943 + 11 47***
1145 + 16 7* 612 + 33 71***
1181 + 41 3* 354 + 22 89***
TA 97a
ion - S9 % inhibition + S9 % inhibition
NOPD 2-AA
884 + 34 1083 + 67
934 + 33 - 682 + 52 43***
948 + 24 - 659 + 41 45***
979 + 84 - 628 + 16 49***
1006 + 54 - 456 + 13 67***
1026 + 75 - 523 + 86 60***
rol; NOPD = 4 -nitro-o-phenylenediamine (10.0 μg/ plate – TA98 and TA97a);
02), in the absence of S9 and B[a]P= benzo[a]pyrene (1.0 μg/ plate – TA 98);
97a); 2-AF = 2-aminofluorene (10.0 μg/ plate – TA102), in the presence of S9.
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The balance between the therapeutic and toxicological
effects of a compound is a very important measure of
the usefulness of a pharmacological drug. Therefore, the
determination of the potential mutagenic effect of any
drug under development is mandatory [26].
In previous studies, Medola et al. [1] showed that HK
not only had no genotoxic effect, but also was effective
in reducing the chromosome damage induced by DXR,
by the rat peripheral blood micronucleus test. Recently,
Resende et al. [12] assessed the possible genotoxic activity
of HK and its influence on the activities of two known
mutagenic agents (DXR and methyl methanesulfonate -
MMS), in the micronucleus test with Chinese hamster
lung fibroblast V79 cells. HK alone had no genotoxic
effect under the conditions tested, but it reduced the
chromosome damage caused by MMS. The reduction
in DXR-induced clastogenicity was observed at lower
concentrations. At higher concentrations, HK acted as a
potentiator of DXR-induced clastogenicity, with the
observation of a significantly higher frequency of micro-
nuclei in the combined treatment when compared to
the positive control.
To complement the above results, the genotoxic∕ muta-
genic activities of HK, and its influence on the activities of
known mutagenic agents, were assessed by comet and
Ames test in this study. According to Witte et al. [27],
experience with genetic toxicology testing over the past few
decades has demonstrated that no single test method is
capable of detecting all types of genotoxic effects. There-
fore, the potential for a chemical to cause genotoxicity is
typically determined by using a battery of in vitro and
in vivo tests.
Through the comet assay, the first and extremely
important observation was the absence of DNA strand
breaks; moreover, there were no gene mutations by the
Ames test in the presence and absence of metabolic acti-
vation. The performance of assays for to assess mutageni-
city, as well as other risks, is essential, given the potential
consumption of HK by the population. The absence of
genotoxic∕ mutagenic effects by HK on V79 cells in the
comet test and against S. typhimurium bacterial strains in
the Ames test is a positive step towards ensuring its safe
use in medicine. Considering the possible use of HK as an
antichagasic drug, a lack of mutagenic effects in animal
cells and bacteria is highly relevant.
On the other hand, the influence of HK on DXR-
induced DNA damage depends on the experimental
conditions used and draws attention to the synergistic
effect that HK may have when combined with other
drugs. In the comet test, the lower concentrations of HK
(0.5; 1.0 and 2.0 μM) significantly reduced the extent of
DNA damage induced by DXR. However, the higher
concentrations of HK (32; 64 and 128 μM), whencombined with DXR, showed a higher rate of class 2
damage than in the cells treated with DXR, which was
statistically significant at concentrations of 32 and 128
μM. However, the extent of DNA damage did not differ
significantly from the frequencies observed in the DXR
treatment. These results are consistent with Resende
et al. [12], who assessed the influence of HK, at the same
concentrations, on DXR-induced genotoxicity.
The chemical structure of DXR favors the generation
of free radicals and the compound can bind to iron and
form complexes with DNA, inducing DNA damage.
Some studies have demonstrated that oxidative damage
is probably related to this formation of free radicals
accompanied by a reduction in antioxidant capacity [28].
Thus, at low concentrations, HK might possibly interfere
in the intercalation of DXR with DNA or scavenge the
generated free radicals. However, at higher doses, HK
may increase the oxidative stress generated by DXR,
since qualitative HPLC analysis showed that no new
compound is formed after the incubation of a mixture of
DXR and HK. HK may act as a “janus” compound, i.e.,
exerting an antioxidant effect at lower concentrations
and a pro-oxidant effect at higher concentrations [12].
The synergistic effect also was observed when HK was
combined with NOPD in the strain TA97a in the absence
of metabolic activation in the Ames test, reinforcing the
hypothesis that the HK may act as a “janus” compound.
In the antimutagenicity evaluated by Ames test, HK
exhibited a protective effect in more than one test strain
and acted against various mutational mechanisms.
Among the antimutagenic activity against directly acting
mutagens, a moderate effect was found only against
frameshift mutations induced by NOPD in the TA98
strain, with the highest % of inhibition at concentration
of 39.0 μg/ plate (26%).
HK did not affect the SA-induced mutagenicity in strain
TA100, MMC in strain TA102 or NOPD in strain 97a.
The protection of the bacterial genome against directly
acting mutagens may be due to the rapid elimination of
mutagens from the bacteria, before their interaction with
the DNA [29]. HK may facilitate or stimulate the bacterial
transmembrane export system to eliminate the mutagens;
it may also interfere with the uptake of mutagens into
bacteria [29,30].
The activity displayed by HK was profoundly increased
by incorporating the microsomal fraction (S9), which is
a mammalian metabolic activation system, into the culture
medium. The results of this experiment show that HK
inhibited B[a]P, AFB1, 2-AF and 2-AA mediated muta-
genesis. The microsomal fraction of rat liver, containing
mixed-function oxidase (MFO) and the cytochrome-
based P450 metabolic oxidation system, can activate B[a]
P to an active mutagen, benzo[a]pyrene-7,8-diol-9,10-ep-
oxide [31]. The mutagenicity of B[a]P was significantly
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This diol epoxide exerts its carcinogenic activity by
alkylating nucleosides on DNA molecules at their bay
region. The reaction occurs primarily with the purine
bases, deoxyguanosine and deoxyadenosine, in DNA
[32]. As a result, bulky stable and depurinating DNA
adducts are formed [33,34]. Insufficient removal of these
DNA adducts prior to replication creates hot spots in
the gene and can result in deactivation of tumor suppressor
genes or activation of oncogenes leading to tumor initiation
[35,36].
There are at least two possible mechanisms by which
HK could decrease B[a]P-DNA adduct formation: by
interacting with reactive intermediates or by interfering
with the action of microsomal enzymes [36]. However,
more studies are needed to confirm these ideas.
HK also reduced the frequency of mutations induced by
the fungal toxin, AFB1, in TA100 with metabolic activation,
resulting in the highest percent inhibition of mutagenicity
(89%). The S. typhimurium tester strain TA100 reveals
base-pair-substitution point mutations [37].
Aflatoxins, a group of potent mycotoxins with mutagenic,
carcinogenic, teratogenic, hepatotoxic and immunosup-
pressive properties, are of particular importance because of
their adverse effects on animal and human health. Aflatox-
ins are produced as secondary metabolites by fungi of
various species of Aspergillus (A. flavus, A. parasiticus and
A. nomius) that grow on a variety of food and feed
commodities. AFB1, which is the most toxic aflatoxin, is
metabolized mainly in the liver to AFB1-8,9-exo-epoxide
and 8,9-endo-epoxide. The exo-epoxide form of AFB1
binds to DNA to form the predominant 8,9-dihydro- 8-
(N7-guanyl)-9-hydroxy AFB1 adduct, leading to a more
stable imidazole ring-opened AFB1–formamidopyrimi-
dine adduct. The pseudo-half-life for loss of 8,9-dihy-
dro-8- (N7-guanyl)-9-hydroxy AFB1 is short, but AFB1–
formamidopyrimidine adducts are stable, accumulate
for several days and remain detectable for several weeks
[38]. This aflatoxin is of particular interest because it is
a frequent contaminant of many food products and one
of the most potent naturally occurring mutagens and
carcinogens known [39].
HK also induced a strong antimutagenic effect, signifi-
cantly diminishing the mutagenicity of 2-AF in TA102 with
metabolic activation, in a dose-dependent manner, by 42 to
52%. 2-AF is converted in rat liver, via N-hydroxy metabo-
lites, to the reactive carcinogenic ester 2-acetylaminofluor-
ene-N-sulfate, which can attack guanine residues in nucleic
acids [31]. The inhibition of 2-AF induced mutagenicity
may be mediated through the inhibition of the MFO (in the
S9 fraction) or inactivation of the activated reactive ester of
2-AF. The S. typhimurium tester strain TA102 is normally
used to detect mutagens that cause oxidative damage andbase-pair-substitution mutations [37]. In this case, anti-
mutagenic activity can be partially ascribed to antioxidant
activity. This speculation is further supported by the
significant antimutagenic effect that the lower concentra-
tions of HK demonstrated against DXR in the comet test,
as well as that against mutagens needing metabolic activa-
tion, where free radical generation is anticipated.
In this study, the antimutagenic property of HK related
to its ability to modulate the xenobiotic-metabolizing
enzymes in the liver, either by preventing the metabolic
activation or by altering the enzymatic activity in the
detoxification pathway to induce the disposal of the
known mutagen [22], was again demonstrated by the
results obtained with the mutagen 2-AA in strain TA97a
with metabolic activation, where 67% inhibition was
observed.
In general, inhibitors of mutagenesis can act in one of
several ways: by inhibiting the interaction between genes
and biochemically reactive mutagens; inhibiting meta-
bolic activation of indirectly-acting mutagens by inacti-
vation of metabolizing enzymes, or interacting with the
pro-mutagens to make them unavailable for the enzym-
atic process [40].Conclusions
In view of the above results and hypotheses, we can state
that the inhibition of mutagenesis is often complex and
involves multiple mechanisms. These results emphasize
that antimutagenic mechanisms of HK cannot be gener-
alized and that it is worth investigating each of them
independently. The importance of this study is that HK
no had to genotoxic / mutagenic effect in the comet and
Ames assays and the DNA protective activity of HK is
not general, therefore, this study demonstrates that
besides the therapeutic potential for trypanosome diseases
free of genotoxic / mutagenic effect, HK can provide a
benefit antimutagenic effect, depending of the type of
DNA damage-inducing agent used.
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